Qiagen N.V. (QGEN)

39,47 +0,24 (+0,61 %) À la clôture : 04:00PM EDT

Qiagen N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
https://www.qiagen.com

Secteur(s): Healthcare
Secteur d’activité: Diagnostics & Research
Employés à temps plein: 5 191

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Thierry Bernard	CEO, MD & Member of Management Board	1,99M	S.O.	1965
Dr. Roland Sackers	CFO, MD & Member of Management Board	1,07M	S.O.	1969
Mr. Antonio Santos	Senior VP & Head of Global Operations	S.O.	S.O.	S.O.
Mr. John Gilardi	Vice President of Corporate Communications & Investor Relations	S.O.	S.O.	S.O.
Ms. Stephany Foster	Senior VP & Head of Human Resources	S.O.	S.O.	1979
Dr. Thomas Schweins	Senior Vice President of Life Science Business Area	S.O.	S.O.	S.O.
Dr. Thomas Theuringer	Senior Director & Head of External Communications	S.O.	S.O.	S.O.
Mr. Jean-Pascal Viola	Senior VP & Head of Molecular Diagnostics Business Area	S.O.	S.O.	S.O.
Dr. Jonathan G. Sheldon Ph.D.	Senior Vice President of Qiagen Digital Insights Business Area	S.O.	S.O.	1972

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Qiagen N.V. en date du 1 avril 2024 est 2. Les scores principaux sont Audit : 1; Société : 3; Droits des actionnaires : 5; Compensation : 3.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.